Dare Bioscience (DARE) Earnings Analysis
Dare Bioscience (DARE) next reports earnings on 2026-08-13, consensus EPS -0.33 USD. Last quarter (2026-05-14) it beat with EPS -0.2 USD vs -0.33 USD est (+39.4%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E -1.17.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DARE next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.33 USD |
| Revenue estimate | 0.00B |
DARE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | -0.2 USD | -0.33 USD | +39.4% | Beat |
| 2026-03-26 | -0.02 USD | -0.24 USD | +91.7% | Beat |
| 2025-11-13 | -0.28 USD | -0.33 USD | +15.2% | Beat |
| 2025-08-14 | -0.45 USD | -0.55 USD | +18.2% | Beat |
| 2025-03-31 | -0.64 USD | -0.66 USD | +3% | Beat |
| 2024-11-14 | -0.55 USD | -0.6 USD | +8.3% | Beat |
| 2024-08-12 | 1.52 USD | -0.57 USD | +366.7% | Beat |
Beat rate: 7/7 (100%) over reported quarters with consensus data.
DARE valuation and analyst view
| Trailing P/E | -1.17 |
|---|---|
| Trailing EPS | -0.82772 USD |
| Price / book | 24.12 |
| Dividend yield | 0.00% |
| Market cap | 0.01B |
| Analyst consensus | Buy (6 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Dare Bioscience (DARE)'s next earnings date?
Dare Bioscience is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.33 USD and revenue estimate of 0.00B.
Did DARE beat earnings last quarter?
In its 2026-05-14 report, DARE posted EPS of -0.2 USD versus a -0.33 USD estimate — a beat of 39.4%.
What is DARE's earnings track record?
Over the last 7 reported quarters with consensus data, DARE beat estimates 7 times (100%).
What is DARE's current P/E ratio and EPS?
DARE trades at a trailing P/E of -1.17 on trailing EPS of -0.8277210338064159 USD.
What do analysts rate DARE?
Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell).